Acrivon Therapeutics Common Stock Analysis
| ACRV Stock | 9.50 0.32 3.26% |
Acrivon Therapeutics Common is undervalued with Real Value of 12.55 and Target Price of 23.13. The main objective of Acrivon Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Acrivon Therapeutics Common is worth, separate from its market price. There are two main types of Acrivon Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Acrivon Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Acrivon Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Acrivon Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Acrivon Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Acrivon Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Acrivon Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Acrivon |
Acrivon Stock Analysis Notes
About 18.0% of the company shares are held by company insiders. The book value of Acrivon Therapeutics was presently reported as 5.38. The company recorded a loss per share of 2.74. Acrivon Therapeutics had not issued any dividends in recent years. For more info on Acrivon Therapeutics Common please contact the company at 617 207 8979 or go to https://www.acrivon.com.Acrivon Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Acrivon Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Acrivon Therapeutics Common or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Acrivon Therapeutics is way too risky over 90 days horizon | |
| Acrivon Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (60.39 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Acrivon Therapeutics generates negative cash flow from operations | |
| Acrivon Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 70.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: ACR-368 shows promise in gynecological cancer trial |
Acrivon Therapeutics Upcoming and Recent Events
Earnings reports are used by Acrivon Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Acrivon Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Acrivon Largest EPS Surprises
Earnings surprises can significantly impact Acrivon Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-28 | 2023-12-31 | -0.73 | -0.86 | -0.13 | 17 | ||
2023-03-28 | 2022-12-31 | -1.09 | -0.8 | 0.29 | 26 |
Acrivon Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Acrivon Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Acrivon Therapeutics Common backward and forwards among themselves. Acrivon Therapeutics' institutional investor refers to the entity that pools money to purchase Acrivon Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corporation | 2023-12-31 | 133.3 K | Dafna Capital Management Llc | 2023-12-31 | 131.4 K | Ubs O'connor Llc | 2023-12-31 | 93.4 K | Northern Trust Corp | 2023-12-31 | 80.1 K | Charles Schwab Investment Management Inc | 2023-12-31 | 68.5 K | D. E. Shaw & Co Lp | 2023-09-30 | 46.8 K | Jpmorgan Chase & Co | 2023-12-31 | 33.3 K | Bridgeway Capital Management, Llc | 2023-12-31 | 32 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 25.6 K | Ra Capital Management, Llc | 2023-12-31 | 4.8 M | Perceptive Advisors Llc | 2023-12-31 | 3 M |
Acrivon Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 293.28 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Acrivon Therapeutics's market, we take the total number of its shares issued and multiply it by Acrivon Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Acrivon Profitablity
Acrivon Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Acrivon Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Acrivon Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Acrivon Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Acrivon Therapeutics' profitability requires more research than a typical breakdown of Acrivon Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.54) | (0.56) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.50) | (0.47) |
Technical Drivers
As of the 25th of April, Acrivon Therapeutics shows the Risk Adjusted Performance of 0.1039, downside deviation of 6.02, and Mean Deviation of 6.45. Acrivon Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Acrivon Therapeutics Common, which can be compared to its peers. Please confirm Acrivon Therapeutics standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Acrivon Therapeutics is priced correctly, providing market reflects its regular price of 9.5 per share. Given that Acrivon Therapeutics has jensen alpha of 1.49, we suggest you to validate Acrivon Therapeutics Common's prevailing market performance to make sure the company can sustain itself at a future point.Acrivon Therapeutics Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Acrivon Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Acrivon Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Acrivon Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Acrivon Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Acrivon Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Acrivon Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Acrivon Therapeutics Predictive Daily Indicators
Acrivon Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Acrivon Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Acrivon Therapeutics Corporate Filings
8K | 24th of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 17th of April 2024 Other Reports | ViewVerify | |
13A | 15th of April 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 11th of April 2024 An amendment to the original Schedule 13D filing | ViewVerify |
8K | 9th of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 29th of March 2024 Other Reports | ViewVerify | |
10K | 28th of March 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Acrivon Therapeutics Forecast Models
Acrivon Therapeutics' time-series forecasting models are one of many Acrivon Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Acrivon Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Acrivon Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Acrivon Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Acrivon shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Acrivon Therapeutics. By using and applying Acrivon Stock analysis, traders can create a robust methodology for identifying Acrivon entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | 0.00 | 0.00 | |
| Operating Profit Margin | 0.00 | 0.00 | |
| Net Profit Margin | 0.00 | 0.00 | |
| Gross Profit Margin | 0.00 | 0.00 |
Current Acrivon Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Acrivon analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Acrivon analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 23.13 | Strong Buy | 9 | Odds |
Most Acrivon analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Acrivon stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Acrivon Therapeutics, talking to its executives and customers, or listening to Acrivon conference calls.
Acrivon Stock Analysis Indicators
Acrivon Therapeutics Common stock analysis indicators help investors evaluate how Acrivon Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Acrivon Therapeutics shares will generate the highest return on investment. By understating and applying Acrivon Therapeutics stock analysis, traders can identify Acrivon Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 29.5 M | |
| Common Stock Shares Outstanding | 22.1 M | |
| Total Stockholder Equity | 121.2 M | |
| Property Plant And Equipment Net | 7.9 M | |
| Cash And Short Term Investments | 127.5 M | |
| Cash | 36 M | |
| Accounts Payable | 5 M | |
| Net Debt | -31.4 M | |
| 50 Day M A | 6.3863 | |
| Total Current Liabilities | 13.3 M | |
| Other Operating Expenses | 67.2 M | |
| Non Current Assets Total | 8.6 M | |
| Non Currrent Assets Other | 251 K | |
| Stock Based Compensation | 11.6 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acrivon Therapeutics Common. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Acrivon Stock analysis
When running Acrivon Therapeutics' price analysis, check to measure Acrivon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics is operating at the current time. Most of Acrivon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics' price. Additionally, you may evaluate how the addition of Acrivon Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is Acrivon Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acrivon Therapeutics. If investors know Acrivon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acrivon Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.74) | Return On Assets (0.26) | Return On Equity (0.41) |
The market value of Acrivon Therapeutics is measured differently than its book value, which is the value of Acrivon that is recorded on the company's balance sheet. Investors also form their own opinion of Acrivon Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Acrivon Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acrivon Therapeutics' market value can be influenced by many factors that don't directly affect Acrivon Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acrivon Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acrivon Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acrivon Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.